First Time Loading...

HLS Therapeutics Inc
TSX:HLS

Watchlist Manager
HLS Therapeutics Inc Logo
HLS Therapeutics Inc
TSX:HLS
Watchlist
Price: 3.94 CAD -4.83% Market Closed
Updated: May 21, 2024

Gross Margin
HLS Therapeutics Inc

86.9%
Current
92%
Average
47.1%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
86.9%
=
Gross Profit
52.8m
/
Revenue
60.8m

Gross Margin Across Competitors

Country Company Market Cap Gross
Margin
CA
HLS Therapeutics Inc
TSX:HLS
125.6m CAD
87%
US
Mckesson Corp
NYSE:MCK
72B USD
4%
US
Cencora Inc
NYSE:COR
43.2B USD
3%
US
Amerisourcebergen Corp
NYSE:ABC
35.4B USD
3%
US
Cardinal Health Inc
NYSE:CAH
23.4B USD
3%
US
Henry Schein Inc
NASDAQ:HSIC
9.4B USD
31%
KR
Celltrion Healthcare Co Ltd
KOSDAQ:091990
12.2T KRW
30%
CN
Sinopharm Group Co Ltd
HKEX:1099
66.9B HKD
8%
IT
Amplifon SpA
MIL:AMP
7.5B EUR
24%
CN
Huadong Medicine Co Ltd
SZSE:000963
57.5B CNY
32%
CN
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
52B CNY
11%
HLS Therapeutics Inc
TSX:HLS
Country CA
Market Cap 125.6m CAD
Gross Margin
87%
Mckesson Corp
NYSE:MCK
Country US
Market Cap 72B USD
Gross Margin
4%
Cencora Inc
NYSE:COR
Country US
Market Cap 43.2B USD
Gross Margin
3%
Amerisourcebergen Corp
NYSE:ABC
Country US
Market Cap 35.4B USD
Gross Margin
3%
Cardinal Health Inc
NYSE:CAH
Country US
Market Cap 23.4B USD
Gross Margin
3%
Henry Schein Inc
NASDAQ:HSIC
Country US
Market Cap 9.4B USD
Gross Margin
31%
C
Celltrion Healthcare Co Ltd
KOSDAQ:091990
Country KR
Market Cap 12.2T KRW
Gross Margin
30%
Sinopharm Group Co Ltd
HKEX:1099
Country CN
Market Cap 66.9B HKD
Gross Margin
8%
Amplifon SpA
MIL:AMP
Country IT
Market Cap 7.5B EUR
Gross Margin
24%
Huadong Medicine Co Ltd
SZSE:000963
Country CN
Market Cap 57.5B CNY
Gross Margin
32%
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
Country CN
Market Cap 52B CNY
Gross Margin
11%

Profitability Report

View the profitability report to see the full profitability analysis for HLS Therapeutics Inc.

Full Profitability Report

See Also

Summary
HLS intrinsic value, competitors valuation, and company profile.
DCF Valuation
HLS stock valuation using Discount Cash Flow valuation method.
Relative Valuation
HLS stock valuation using valuation multiples.
Wall Street Estimates
HLS price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
HLS stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
86.9%
=
Gross Profit
52.8m
/
Revenue
60.8m
What is the Gross Margin of HLS Therapeutics Inc?

Based on HLS Therapeutics Inc's most recent financial statements, the company has Gross Margin of 86.9%.

ALPHA SPREAD
Join more than 139,400+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.